Health-related Quality of Life in Korean Patients With Rheumatic Diseases
- Conditions
- Scleroderma, Systemic
- Interventions
- Other: validated Korean version of the SF36 and EQ-5D
- Registration Number
- NCT03257878
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
To compare the health related quality of life of patients with systemic sclerosis with other rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus and Sjogren's syndrome.
- Detailed Description
Systemic sclerosis (SSc) is a connective tissue disease characterized by vasculopathy, fibrosis, and autoimmunity. The prognosis of the disease depends on the nature and severity of organ involvement. Patients with SSc suffer from digital ulceration, arthritis, progressive skin tightening, and joint contractures that cause pain and limitation of limb function. The cardiopulmonary system may also be severly affected by SSc in the form of interstitial lung disease and pulmonary arterial hypertension, which leads to reduction in exercise capacity and symptomatic dyspnea. Gastrointestinal involvement by SSc may cause malnutrition, and SSc renal crises may result in renal failure. In addition, cosmetic disfigurement resulting from facial and limb skin involvement may lead to social isolation, mood problems, and significant work disability.
It has been reported that health related quality of life (HRQoL) is significantly impared in SSc patients compared to the general population. Moreover, the degree of impairment in SSc patients was comparable to those who suffered from other chronic illnesses such as heart and lung disease, hypertension, diabetes mellitus, and depression. However, there were no studies yet comparing the HRQoL of SSc patients with other rheumatic diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Especially, information regarding the impact of SSc on functioning and HRQoL in Korean patients is lacking.
Therefore, the investigators plan to compare the functioning and HRQoL of patients with SSc with other rheumatic diseases, such as RA, SLE, and Sjogrens's syndrome, and healthy controls. A validated Korean version of the Medical Outcomes Study Short Form 36 (SF36) questionnaire and the EuroQol five dimensions questionnaire (EQ-5D) will be used in this study.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- Males or females > 18 years at time of consent
- Patients able to understand written and spoken Korean
- Patients who have been informed about the research
- Patients with SSc meeting the 1980 ACR criteria or 2013 ACR/EULAR criteria for SSc
- Patients with RA meeting the 2010 ACR/EULAR criteria
- Patients with SLE meeting the 1997 ACR criteria or 2012 SLICC criteria
- Patients with Sjogren's syndrome meeting the 2002 AECG criteria or 2012 ACR criteria
- Controls : without any rheumatic diseases
- Severe mental retardation
- Any impairment of ability to understand making self-evaluation impossible (using a validated Korean version of the SF36 and EQ-5D)
- Anyone with other rheumatic diseases
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Sjogren's syndrome validated Korean version of the SF36 and EQ-5D validated Korean version of the SF36 and EQ-5D Systemic lupus erythematosus (SLE) validated Korean version of the SF36 and EQ-5D validated Korean version of the SF36 and EQ-5D Systemic sclerosis (SSc) validated Korean version of the SF36 and EQ-5D validated Korean version of the SF36 and EQ-5D Rheumatoid arthritis (RA) validated Korean version of the SF36 and EQ-5D validated Korean version of the SF36 and EQ-5D Control validated Korean version of the SF36 and EQ-5D validated Korean version of the SF36 and EQ-5D
- Primary Outcome Measures
Name Time Method comparison of physical component scores (PCS) of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion
- Secondary Outcome Measures
Name Time Method comparison of mental health (MH) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of the scores of the EQ-5D questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of mental component scores (MCS) of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of physical functioning (PF) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of physical role (PR) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of bodily pain (BP) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of general health (GH) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of vitality (VT) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of social functioning (SF) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion comparison of emotional role (ER) scores of the SF 36 questionnaire between patients with systemic sclerosis and other rheumatic diseases once at inclusion
Trial Locations
- Locations (1)
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of